351 related articles for article (PubMed ID: 36300092)
1. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.
Saoudi González N; Castet F; Élez E; Macarulla T; Tabernero J
Front Oncol; 2022; 12():1021772. PubMed ID: 36300092
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in gastrointestinal cancers.
Grierson P; Lim KH; Amin M
J Gastrointest Oncol; 2017 Jun; 8(3):474-484. PubMed ID: 28736635
[TBL] [Abstract][Full Text] [Related]
3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
4. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic treatment of gastrointestinal malignancies.
Salmon JS; Lockhart AC; Berlin J
Cancer Invest; 2005; 23(8):712-26. PubMed ID: 16377590
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
Procaccio L; Damuzzo V; Di Sarra F; Russi A; Todino F; Dadduzio V; Bergamo F; Prete AA; Lonardi S; Prenen H; Palozzo AC; Loupakis F
Drug Saf; 2019 Feb; 42(2):159-179. PubMed ID: 30649744
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
8. [Anti-angiogenic therapy for gastrointestinal tumours].
Graepler F; Gregor M; Lauer UM
Z Gastroenterol; 2005 Mar; 43(3):317-29. PubMed ID: 15765305
[TBL] [Abstract][Full Text] [Related]
9. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis in gastrointestinal tumors: current challenges.
Nandikolla AG; Rajdev L
Transl Gastroenterol Hepatol; 2016; 1():67. PubMed ID: 28138633
[TBL] [Abstract][Full Text] [Related]
11. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.
Qin S; Li A; Yi M; Yu S; Zhang M; Wu K
J Hematol Oncol; 2019 Mar; 12(1):27. PubMed ID: 30866992
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapy in Metastatic Hepatocellular Carcinoma.
Elms D; Badami A; Dhanarajan A
Curr Gastroenterol Rep; 2022 May; 24(5):65-71. PubMed ID: 35416635
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic strategies in gastrointestinal malignancies.
Whisenant J; Bergsland E
Curr Treat Options Oncol; 2005 Sep; 6(5):411-21. PubMed ID: 16107244
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
Kourie HR; Tabchi S; Ghosn M
World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
[TBL] [Abstract][Full Text] [Related]
15. The microbiome and hepatobiliary-pancreatic cancers.
Mima K; Nakagawa S; Sawayama H; Ishimoto T; Imai K; Iwatsuki M; Hashimoto D; Baba Y; Yamashita YI; Yoshida N; Chikamoto A; Baba H
Cancer Lett; 2017 Aug; 402():9-15. PubMed ID: 28527946
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
Harris WP; Wong KM; Saha S; Dika IE; Abou-Alfa GK
Semin Oncol; 2018 Jun; 45(3):116-123. PubMed ID: 30348531
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for gastric cancer: current status.
Yoong J; Michael M; Leong T
Drugs; 2011 Jul; 71(11):1367-84. PubMed ID: 21812503
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
19. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.
Alabraba E; Joshi H; Bird N; Griffin R; Sturgess R; Stern N; Sieberhagen C; Cross T; Camenzuli A; Davis R; Evans J; O'Grady E; Palmer D; Diaz-Nieto R; Fenwick S; Poston G; Malik H
Eur J Surg Oncol; 2019 Sep; 45(9):1660-1667. PubMed ID: 31014988
[TBL] [Abstract][Full Text] [Related]
20. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
Eso Y; Seno H
Therap Adv Gastroenterol; 2020; 13():1756284820948773. PubMed ID: 32913444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
